Drug Interactions

This is such a common and complex occurrence and fraught with all sorts of potentialities that the possible permutations and combinations seem limitless. We need to keep it real.

Body drug-metabolism (or pharmacokinetics) can cause their inactivation or produce active metabolites, which may or may not have similar actions (pharmacodynamics) to the parent: they may even be more active than the parent drug, have a totally new action, or be toxic.

Human physiology, thankfully, is remarkably resilient: homeostatic mechanisms kick in to keep things at steady-state. Nevertheless, it behooves us to keep abreast of the common, the classic, and the critical (the three C’s) — in this field. Much medical error is from inappropriate drug use, and much inappropriate drug use relates to drug-drug interactions. [There is something to be said for de-prescribing, especially in the elderly].

As a rule of thumb: lipophilics to the liver; hydrophilics to the kidney.

Microsomal enzymes

  • cytochrome P450
  • flavin mono-oxygenase (FMO3)

Drug Metabolism

Phase I: Oxidation / Reduction / Hydrolysis of the xenobiotic (foreign chemical)
Phase II: Conjugation — if you can’t do any of the above, attach a moiety on to the parent molecule to make it more water soluble (after which, they can be excreted in the urine)
Phase III: energy-dependent excretion — do whatever it takes to force this intruder off your property

Note: Drug interactions from hepatic metabolism are nearly always due to interactions at Phase I enzymes rather than at Phase II — i.e. commonly due to interaction at cytochrome P450 enzymes, some of which are genetically absent!

Some people have point mutations at one (or more) of the nucleic acids in the DNA sequence expressing a given cytochrome P450 isozyme. As a result, the enzyme may be absent or have low, or no, metabolizing activity for drugs that are usually metabolized by that enzyme.

Further Reading

Leave a Reply